Fusion Antibodies (LON:FAB) Announces Earnings Results

Fusion Antibodies (LON:FAB) released its earnings results on Monday. The company reported GBX (1.20) EPS for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative net margin of 54.45% and a negative return on equity of 97.87%.

Fusion Antibodies Stock Performance

Shares of LON:FAB traded up GBX 0.25 on Friday, hitting GBX 11. 88,580 shares of the company were exchanged, compared to its average volume of 419,787. The company’s 50 day moving average price is GBX 10.80 and its two-hundred day moving average price is GBX 12.09. The firm has a market capitalization of £13.77 million, a price-to-earnings ratio of -7.33 and a beta of 1.24. The company has a debt-to-equity ratio of 20.41, a quick ratio of 2.36 and a current ratio of 2.82. Fusion Antibodies has a one year low of GBX 9 and a one year high of GBX 21.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.